Clinical Trials on Advanced Non-Small Cell Lung Cancer in China

Total 1853 results

Shandong Cancer Hospital and Institute
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Hypofraction Radiotherapy in Patients With NSCLC

Non-Small-Cell Lung Cancer

China
Guangzhou Medical University

Unknown

Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC

Non Small Cell Lung Cancer

China
The First Affiliated Hospital of Guangzhou Medical...

Unknown

A Study to Explore Treatment Regimens and Clinical Outcomes of the NSCLC Patients With Different Dirver Genes

Non-small Cell Lung Cancer

China
Sun Yat-sen University
Wu Jieping Medical Foundation

Completed

Gefitinib 500mg Versus 250mg in Patients With NSCLC With Stable Disease After a Month Treatment of Gefitinib 250mg

Non-small Cell Lung Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer

Stage II-IIIB(N2) Non-small Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-B01D1 Combined With Osimertinib Mesylate Tablets in Patients With Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Shandong New Time Pharmaceutical Co., LTD

Not yet recruiting

A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NSCLC | Non-small Cell Lung Cancer | PD-1

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer

EGF-R Positive Non-Small Cell Lung Cancer

China
Shanghai General Hospital, Shanghai Jiao Tong University...

Unknown

High Dose Radiation Therapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Shanghai Gebaide Biotechnology Co., Ltd.

Unknown

A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection

Non-small-cell Lung Cancer (NSCLC) Stage IV

China
Tianjin Medical University Cancer Institute and...

Completed

Study of M2ES With Paclitaxel/Carboplatin (TC Regimen) in Advanced Non Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

China
Zeng Jian

Recruiting

A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC

Non Small Cell Lung Cancer

China
Second Xiangya Hospital of Central South University
Geneplus-Beijing Co. Ltd.

Not yet recruiting

ctDNA-MRD in Stage IIIB-C NSCLC Patients Treated With Induction Chemoimmunotherapy

Non-small Cell Lung Cancer

China
The First Affiliated Hospital of Guangzhou Medical...

Recruiting

Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression

Non-small Cell Lung Cancer

China
Qilu Pharmaceutical Co., Ltd.

Recruiting

To Evaluate the Efficacy of QLH11811 in Advanced NSCLC Patients With EGFR Mutation

Non-small Cell Lung Cancer

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation

Non-small Cell Lung Cancer

China
Shenzhen TargetRx, Inc.
First Affiliated Hospital Bengbu Medical College

Completed

TGRX-326 Phase I/II Pharmacokinetic Study

Non Small Cell Lung Cancer

China
Second Affiliated Hospital, School of Medicine,...

Active, not recruiting

Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE） (neoSCORE)

Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients

Non-small-cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations

Non-Small Cell Lung Cancer With HER2- Mutations

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer

EGF-R Positive Non-Small Cell Lung Cancer

China
Merck Sharp & Dohme LLC

Completed

A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study

Non-small Cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Unknown

Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC

Non-small Cell Lung Cancer | First-line Treatment

China
Shanghai University of Traditional Chinese Medicine
Shanghai Chest Hospital; Shanghai Cancer Hospital, China; Shanghai Pulmonary... and other collaborators

Unknown

Efficacy Study of Comprehensive Rehabilitation Program Plus Chemotherapy in Postoperative NSCLC Patients

Non-small Cell Lung Cancer

China
Chinese Academy of Sciences
Guangdong Academy of Medical Sciences; West China Hospital; Shanghai Pulmonary...

Unknown

Therapeutic Resistance Prediction of Tyrosine Kinase Inhibitors

Non-small Cell Lung Cancer

China
Peking Union Medical College Hospital

Unknown

Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients

Non-small Cell Lung Cancer | Effects of Chemotherapy

China
Fudan University

Unknown

Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer (APPEAL)

Lung Cancer, Non-small Cell | EGFR Gene Mutation | EGFR T790M

China
The First Affiliated Hospital of Guangdong Pharmaceutical...
University of Technology, Sydney; Guangzhou Anjie Biomedical Technology Co....

Unknown

Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC

Non-small Cell Lung Cancer | Lung Neoplasm Malignant

China
Sun Yat-sen University

Active, not recruiting

Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy

Stage III Non-small-cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung Cancer

Squamous Non-small Cell Lung Cancer

China
Second Affiliated Hospital, School of Medicine,...
Tongji Hospital; Qilu Hospital of Shandong University; First Hospital of China... and other collaborators

Recruiting

A Study With Pembrolizumab for Non-small Cell Lung Cancer (NSCLC)

Pembrolizumab | Non-small-lung-cell Cancer, NSCLC

China
Tianjin Hemay Pharmaceutical Co., Ltd
Hainan General Sanyang Pharmaceutical Co., Ltd

Terminated

Study Evaluating Hemay020 In Subjects With Advanced Solid Cancer

Neoplasms，Non-Small Cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.
Sun Yat-sen University; Shanghai Pulmonary Hospital, Shanghai, China

Suspended

A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer (NSCLC)

China
Peking University People's Hospital

Unknown

Surgical Treatment of Elderly Patients With cT1N0M0 Non-small Cell Lung Cancer Comparison Between Sublobar Resection and Lobectomy (STEPS)

Non-small Cell Lung Cancer

China
Lu Shun

Recruiting

An Early Stage Study to Evaluate Oba01 for Injection in Patients With DR5 Positive LA/mNSCLC

Non-small Cell Lung Cancer Metastatic

China
The First Affiliated Hospital of Guangzhou Medical...

Not yet recruiting

Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC (ANSWER)

Non-Small Cell Lung Cancer Stage IIIA

China
Genor Biopharma Co., Ltd.
Hutchison Medipharma Limited

Recruiting

Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib

Metastatic Non-small Cell Lung Cancer

China
Shanghai JMT-Bio Inc.

Active, not recruiting

JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations

Local Advanced or Metastatic NSCLC | Harboring EGFR Common Mutation

China
Xinqiao Hospital of Chongqing

Completed

Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC

Non-Small-Cell Lung Cancer Stage IV

China
Henan Cancer Hospital

Recruiting

Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure

Non-Squamous Non-Small Cell Lung Cancer

China
Shanghai EpimAb Biotherapeutics Co., Ltd.
Labcorp Corporation of America Holdings, Inc

Not yet recruiting

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma | EGFR Mutation-Related Tumors

United States, China
Boehringer Ingelheim

Completed

The START Study Observes Afatinib as First-line Treatment and Sequential Therapy in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Nonsmall Cell Lung Cancer

Non-squamous, Non-Small Cell Lung Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China

Active, not recruiting

CX3CR1+T Cell Predict Immunotherapy Efficacy

Non-small Cell Lung Cancer

China
Beijing Cancer Prevention & Treatment Society
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Recruiting

A Prospective, Multicenter, Non-interventional, Real-world Study to Characterize Changes in Molecular Markers After Three Weeks of Targeted Therapy With Oxitinib in EGFRm NSCLC (pre-FLAME)

Non Small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)

Non Small Cell Lung Cancer

China
Guangzhou Institute of Respiratory Disease

Recruiting

To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

China
Guangzhou Institute of Respiratory Disease

Recruiting

A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Anhui Provincial Hospital

Recruiting

Hypofraction Radiotherapy for Locally Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Toxicity Due to Radiotherapy

China
Akeso

Completed

A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Lung Cancer Non-Small Cell Stage IIIB/IIIC/IV

China
Zhejiang Cancer Hospital

Active, not recruiting

Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study. (NSCLC)

Non-small Cell Lung Cancer | PDL1 Gene Mutation

China

Clinical Trials on Advanced Non-Small Cell Lung Cancer in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations